Your session is about to expire
← Back to Search
Chemotherapy for Breast Cancer
Study Summary
This trial is testing paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide to see if it is effective in treating patients with breast cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My breast tumor is at least 1 cm big, or I have measurable axillary adenopathy.Your kidney function is too high, with a filtration rate of more than 30 milliliters per minute.My breast cancer was confirmed by a needle or small cut biopsy.I have stage II-III breast cancer and plan to have surgery after initial treatment, but I don't have inflammatory breast cancer.I haven't had serious bleeding episodes in the last 6 months.I am not pregnant or nursing and agree to use non-hormonal birth control during the study.My heart's pumping ability is within the normal range.My tumor is mostly negative for hormone receptors.You have a platelet count of more than 100,000 per microliter.My kidney function test shows less than 1g of protein in 24 hours.Your ALT blood test results are not more than 2.5 times the normal range.Your total bilirubin level is no more than 1.5 times the upper limit of normal.My cancer is in more than one location but meets the study's requirements.I can carry out all my usual activities without help.I don't have any serious wounds, ulcers, fractures, or recent major surgeries.You have more than 1,000 granulocytes in a microliter of blood.I haven't had chemotherapy, hormone therapy, or radiation for this cancer.My blood clotting time is within safe limits, or if on warfarin, my INR is stable and <=3 without bleeding risks.I do not have severe nerve pain or numbness.My invasive tumor is HER2-negative.The amount of protein in your urine is not too high.I have not had heart failure, a heart attack, stroke, uncontrolled high blood pressure, or severe artery disease in the last year.Women who could become pregnant have a negative pregnancy test.
- Group 1: Arm I (paclitaxel, doxorubicin, cyclophosphamide)
- Group 2: Arm II (paclitaxel, ddAC, bevacizumab)
- Group 3: Arm III (paclitaxel, ddAC, carboplatin)
- Group 4: Arm IV (paclitaxel, ddAC, bevacizumab, carboplatin)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any prior experiments that have studied Paclitaxel's effects?
"In 1997, the first clinical trial of Paclitaxel was conducted at Spectrum Health Hospital - Butterworth Campus. Since then, there have been 4015 completed trials and 2239 active ones; many of which are set in Saint Louis, Missouri."
Has there been any precedent for this research?
"At present, there are 2239 ongoing Paclitaxel experiments across 87 nations and 3990 cities. The first trial for this drug was executed in 1997 by Alfacell with 300 patients taking part and concluding at Phase 3 of the drug approval process. Subsequent to that inaugural experiment, 4015 further trials have been completed successfully."
To what extent might Paclitaxel be hazardous to patients?
"Paclitaxel has been evaluated for safety, resulting in a rating of 2 on our scale. This is because this drug's efficacy has not yet been proven and there are only limited data regarding its safety."
How many subjects are currently participating in this experimental protocol?
"At present, this trial is not recruiting patients. Although the first posting for the study was on May 15th 2009 and it was last updated August 30 2022, no participants are needed currently. For those looking to join a medical study related to breast cancer or Paclitaxel in particular, there are 4,567 and 2,239 studies actively searching for volunteers respectively."
Is there a broad range of sites facilitating this research across North America?
"This clinical trial is currently recruiting individuals from a total of 100 sites, including Saint Louis, Honolulu and Minneapolis. To reduce travel expenses associated with the enrolment process, it is important to select the closest location available."
What afflictions is Paclitaxel typically deployed to manage?
"Paclitaxel is widely used to treat lymphoma, non-Hodgkin's sarcoma linked to AIDS, and recurrent cervical cancer."
Is enrollment currently active for this clinical trial?
"This research programme is no longer accepting patients. The trial was first published on May 15th 2009 and last updated on August 30th 2022. Presently, there are 4567 clinical trials recruiting breast cancer candidates and 2239 Paclitaxel studies in search of participants."
Share this study with friends
Copy Link
Messenger